Insider Buying: Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Acquires 3,200 Shares of Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel bought 3,200 shares of Greenwich LifeSciences stock in a transaction that occurred on Monday, December 30th. The shares were bought at an average cost of $11.12 per share, with a total value of $35,584.00. Following the acquisition, the chief executive officer now directly owns 5,539,302 shares in the company, valued at $61,597,038.24. This trade represents a 0.06 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Greenwich LifeSciences Stock Performance

Shares of GLSI stock opened at $12.88 on Friday. The company has a market capitalization of $169.37 million, a price-to-earnings ratio of -16.10 and a beta of 1.61. The company has a 50-day simple moving average of $13.20 and a 200 day simple moving average of $14.18. Greenwich LifeSciences, Inc. has a 52 week low of $8.00 and a 52 week high of $21.44.

Institutional Trading of Greenwich LifeSciences

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC raised its stake in Greenwich LifeSciences by 4.6% in the 3rd quarter. Geode Capital Management LLC now owns 133,550 shares of the company’s stock worth $1,919,000 after purchasing an additional 5,861 shares in the last quarter. State Street Corp raised its stake in Greenwich LifeSciences by 4.4% in the 3rd quarter. State Street Corp now owns 71,408 shares of the company’s stock worth $1,026,000 after purchasing an additional 3,005 shares in the last quarter. Garden State Investment Advisory Services LLC acquired a new stake in Greenwich LifeSciences in the 3rd quarter worth about $253,000. Bank of New York Mellon Corp acquired a new stake in Greenwich LifeSciences in the 2nd quarter worth about $264,000. Finally, Barclays PLC raised its stake in Greenwich LifeSciences by 323.3% in the 3rd quarter. Barclays PLC now owns 8,560 shares of the company’s stock worth $123,000 after purchasing an additional 6,538 shares in the last quarter. Institutional investors and hedge funds own 4.16% of the company’s stock.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.